AMARIN CORP PLC\UK (AMRN) — SEC Financial Statements & Analysis

AMARIN CORP PLC\UK (AMRN) is a pharmaceutical preparations company, incorporated in X0. AMARIN CORP PLC\UK trades on Nasdaq as: AMRN. AMARIN CORP PLC\UK (AMRN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29. Based on that filing, AMARIN CORP PLC\UK carries a market cap of $331.91M, a P/E ratio of -12.24x, a P/B ratio of 0.75x, a P/S ratio of 1.78x, an enterprise value of $188.35M, and an EV/EBITDA multiple of -4.97x. On profitability, it posts a gross margin of 41.96%, an operating margin of -21.89%, a net margin of -14.56%, a Return on Equity (ROE) of -5.97%, a Return on Assets (ROA) of -4.19%, and a Return on Invested Capital (ROIC) of -12.10%. Per share, it reports EPS of $-1.30, diluted EPS of $-1.30, free cash flow per share of $0.75, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -15.10% year-over-year, net income growth of -73.82% year-over-year, and EPS growth of -73.94% year-over-year. On the balance sheet, it maintains a current ratio of 3.67x, a quick ratio of 2.48x, working capital of $438.56M, a debt-to-equity ratio of 0.41x, a debt ratio of 0.29, an interest coverage ratio of -7.83x, free cash flow of $15.57M (TTM), and net debt of $-143.56M. Figures sourced from SEC EDGAR.

Market Cap

$331.91M

P/E TTM

-12.24x

EPS TTM

$-1.30

P/B TTM

0.75x

ROE TTM

-5.97%

ROA TTM

-4.19%

Debt To Equity

0.41x

Free Cash Flow TTM

$15.57M

Net Revenue TTM Growth 1Y

-15.10%

Data as of 2026-06-30 · Source: SEC EDGAR